cabotegravir + tenofovir disoproxil fumarate + emtricitabine

This is a combination regimen consisting of three antiretroviral agents used for the treatment and prevention of HIV-1 infection. Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome, thereby inhibiting HIV replication. Tenofovir disoproxil fumarate and emtricitabine are both nucleoside reverse transcriptase inhibitors (NRTIs); they inhibit reverse transcriptase, an enzyme crucial for viral replication. This triple combination is not available as a single co-formulated product but may be used together in clinical practice or research settings to provide comprehensive antiretroviral coverage, particularly in pre-exposure prophylaxis (PrEP) or treatment regimens where resistance or tolerability issues necessitate such combinations[1][4][5]. Each component has established efficacy in reducing HIV acquisition risk and suppressing viral load.

Brand names

TruvadaApretude

Other names

TDF-FTC + CAB-LATDF/FTC + CAB-LAtenofovir disoproxil fumarate/emtricitabine + cabotegravir long-acting